^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Melblez Kit (melphalan hepatic delivery system)

    i
    Other names: Chemostat melphalan, Chemosat, Delcath Hepatic Chemostat Delivery System for melphalan, CS-PHP-melphalan, melphalan drug delivery system, Generation Two Chemostat Delivery System for melphalan, melphalan/HDS
    Company:
    Delcath, Medac
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    1m
    Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease (clinicaltrials.gov)
    P2, N=90, Recruiting, Delcath Systems Inc. | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jan 2026
    Enrollment open • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification • HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Melblez Kit (melphalan hepatic delivery system)
    1m
    PHP-MBC-202: Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients with Metastatic Breast Cancer (2025-521966-91-00)
    P1/2, N=12, Not yet recruiting, Delcath Systems Inc.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification • HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Melblez Kit (melphalan hepatic delivery system)
    2ms
    Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis (clinicaltrials.gov)
    P1/2, N=15, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    melphalan • Opdualag (nivolumab/relatlimab-rmbw) • Melblez Kit (melphalan hepatic delivery system) • relatlimab (BMS-986016)
    4ms
    Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis (clinicaltrials.gov)
    P1/2, N=15, Not yet recruiting, University of Wisconsin, Madison
    New P1/2 trial
    |
    melphalan • Opdualag (nivolumab/relatlimab-rmbw) • Melblez Kit (melphalan hepatic delivery system) • relatlimab (BMS-986016)
    4ms
    Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=18, Recruiting, H. Lee Moffitt Cancer Center and Research Institute
    New P2 trial
    |
    Kimmtrak (tebentafusp-tebn) • Melblez Kit (melphalan hepatic delivery system)
    7ms
    Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease (clinicaltrials.gov)
    P2, N=90, Recruiting, Delcath Systems Inc. | Not yet recruiting --> Recruiting | Initiation date: May 2025 --> Aug 2025
    Enrollment open • Trial initiation date
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • Melblez Kit (melphalan hepatic delivery system)
    1year
    Evaluation of the Safety and Efficacy of Treatment W/High Dose Melphalan Given Directly Into the Liver Followed by Treatment W/approved Cancer Treatment or Approved Cancer Treatment Alone in Patients W/ Metastatic Breast Cancer W/liver Dominant Disease (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Delcath Systems Inc.
    New P2 trial
    |
    capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Melblez Kit (melphalan hepatic delivery system)
    over1year
    Evaluation of the Safety and Efficacy of Treatment W/High Dose Melphalan Given Directly Into the Liver Followed by Treatment W/approved Cancer Treatment or Approved Cancer Treatment Alone in Patients W/ Metastatic Colorectal Cancer W/liver Dominant Disease (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Delcath Systems Inc.
    New P2 trial
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • Melblez Kit (melphalan hepatic delivery system)
    over2years
    An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma (clinicaltrials.gov)
    P3, N=30, Active, not recruiting, Delcath Systems Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Melblez Kit (melphalan hepatic delivery system)
    over2years
    FOCUS: Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma (clinicaltrials.gov)
    P3, N=102, Completed, Delcath Systems Inc. | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Aug 2023
    Trial completion • Trial completion date
    |
    Melblez Kit (melphalan hepatic delivery system)